EUVIMEDEUVIMED entdecken
Leitlinie

Recommendations for the Pharmacological Treatment of Osteoporosis – Update 2023 of the German Osteoporosis Guideline

Ralf Schmidmaier, Peyman Hadji, Peter Kern, Michael Drey, Franz Jakob, Friederike Thomasius

Osteologie · 01.05.2023 · 32 (02) · 115-122

DOI: 10.1055/a-2034-6086 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Osteologie, erschienen am 01.05.2023. Verfasst von Ralf Schmidmaier und 5 weiteren Autor:innen. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 58 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

The German osteoporosis guideline was updated on the basis of a systematic literature review and through a structured consensus process by an interdisciplinary, international (Germany, Austria, Switzerland) expert group representing the 20 member societies of the Joint Osteological Association (DVO) and patient advocacy organizations (BfO). This manuscript summarizes the changes in the German osteoporosis guideline with regard to pharmacological interventions and offers pragmatic pathways for implementation.

Method

Systematic literature search and structured consensus building according to AWMF regulations.

Results

The sclerostin antibody romosozumab was adopted into the guideline. In addition, the effectiveness of teriparatide was re-evaluated. For both bone anabolic agents evidence from randomized trials underlined a superiority over oral bisphosphonates with regard to fracture risk reduction. Between the antiresorptive treatments, differences regarding superiority/inferiority could only be shown with respect to surrogate parameters, not with regard to fractures. Data about the duration of treatment of all available drugs is limited. All non-bisphosphonate treatments require follow-up treatment.

Conclusion

An individualized treatment concept should be developed in a shared decision process, including a bone anabolic-first strategy in high-risk patients. Recommendations on treatment duration, drug holidays and sequential strategies should be considered.

Zitieren

APA

Schmidmaier, R., Hadji, P., Kern, P., Drey, M., Jakob, F., & Thomasius, F. (2023). Recommendations for the Pharmacological Treatment of Osteoporosis – Update 2023 of the German Osteoporosis Guideline. Osteologie, 32(02), 115-122. https://doi.org/10.1055/a-2034-6086

Vancouver

Schmidmaier R, Hadji P, Kern P, Drey M, Jakob F, Thomasius F. Recommendations for the Pharmacological Treatment of Osteoporosis – Update 2023 of the German Osteoporosis Guideline. Osteologie. 2023;32(02):115-122. doi:10.1055/a-2034-6086

BibTeX
@article{Schmidmaier2023,
  author = {Schmidmaier, Ralf and Hadji, Peyman and Kern, Peter and Drey, Michael and Jakob, Franz and Thomasius, Friederike},
  title = {Recommendations for the Pharmacological Treatment of Osteoporosis – Update 2023 of the German Osteoporosis Guideline},
  journal = {Osteologie},
  year = {2023},
  volume = {32},
  number = {02},
  pages = {115--122},
  doi = {10.1055/a-2034-6086}
}
Kostenlos starten →